Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibudilast in COVID-19 at Risk for ARDS
NCT04429555Phase 2Completed
- Sponsor
- MediciNova, Inc.
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibudilast in coronavirus disease 2019 (COVID-19), sponsored by MediciNova, Inc.. Started Jan 2021; status: completed.
02
Drugs
ibudilast
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04429555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429555.